423 related articles for article (PubMed ID: 15589595)
21. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer.
Stefano R; Agostara B; Calabrò M; Campisi I; Ravazzolo B; Traina A; Miele M; Castagnetta L
Ann N Y Acad Sci; 2004 Dec; 1028():463-72. PubMed ID: 15650272
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of cyclooxygenase-2 and thymidine phosphorylase as a prognostic indicator in patients with FIGO stage IIB squamous cell carcinoma of uterine cervix treated with radiotherapy and concurrent chemotherapy.
Pyo H; Kim YB; Cho NH; Suh CO; Park TK; Yun YS; Kim GE
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):725-32. PubMed ID: 15936552
[TBL] [Abstract][Full Text] [Related]
23. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract][Full Text] [Related]
24. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
[TBL] [Abstract][Full Text] [Related]
25. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
26. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimäki A; Sivula A; Lundin J; Lundin M; Salminen T; Haglund C; Joensuu H; Isola J
Cancer Res; 2002 Feb; 62(3):632-5. PubMed ID: 11830510
[TBL] [Abstract][Full Text] [Related]
29. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of KIT expression in small cell lung cancer.
López-Martin A; Ballestín C; Garcia-Carbonero R; Castaño A; Lopez-Ríos F; López-Encuentra A; Sánchez-Cespedes M; Castellano D; Bartolomé A; Cortés-Funes H; Paz-Ares L
Lung Cancer; 2007 Jun; 56(3):405-13. PubMed ID: 17420067
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
32. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
33. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
34. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
35. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
36. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Denkert C; Winzer KJ; Müller BM; Weichert W; Pest S; Köbel M; Kristiansen G; Reles A; Siegert A; Guski H; Hauptmann S
Cancer; 2003 Jun; 97(12):2978-87. PubMed ID: 12784332
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
39. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Baroni G; Taddei A; Taddei GL
Gynecol Oncol; 2004 Mar; 92(3):806-12. PubMed ID: 14984945
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
